mRNA is a rather versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies.
麻豆原创 Analysis and Insights: Global mRNA Vaccine And Therapeutics 麻豆原创
The global mRNA Vaccine And Therapeutics market is projected to grow from US$ 38750 million in 2023 to US$ 51630 million by 2029, at a Compound Annual Growth Rate (CAGR) of 4.9% during the forecast period.
Global core mRNA vaccines & therapeutics manufacturers include Moderna Therapeutics, CureVac etc. The top 3 companies hold a share about 65%. Europe is the largest market, with a share about 10%, followed by Asia Pacific and North America.
Report Includes
This report presents an overview of global market for mRNA Vaccine And Therapeutics market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.
This report researches the key producers of mRNA Vaccine And Therapeutics, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for mRNA Vaccine And Therapeutics, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the mRNA Vaccine And Therapeutics revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global mRNA Vaccine And Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for mRNA Vaccine And Therapeutics revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Argos Therapeutics, BioNTech, CureVac, eTheRNA, Ethris, In-Cell-Art, Moderna Therapeutics, Sangamo Therapeutics and Tiba Biotechnology, etc.
By Company
Argos Therapeutics
BioNTech
CureVac
eTheRNA
Ethris
In-Cell-Art
Moderna Therapeutics
Sangamo Therapeutics
Tiba Biotechnology
Translate Bio
Segment by Type
Infectious Disease
Cancer
Others
Segment by Application
Hospital
Research Institual
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East, Africa, and Latin America
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of mRNA Vaccine And Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of mRNA Vaccine And Therapeutics companies鈥� competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: China by type and by application revenue for each segment.
Chapter 9: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, mRNA Vaccine And Therapeutics revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global mRNA Vaccine And Therapeutics 麻豆原创 Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Infectious Disease
1.2.3 Cancer
1.2.4 Others
1.3 麻豆原创 by Application
1.3.1 Global mRNA Vaccine And Therapeutics 麻豆原创 Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Research Institual
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global mRNA Vaccine And Therapeutics 麻豆原创 Perspective (2018-2029)
2.2 Global mRNA Vaccine And Therapeutics Growth Trends by Region
2.2.1 mRNA Vaccine And Therapeutics 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 mRNA Vaccine And Therapeutics Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 mRNA Vaccine And Therapeutics Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 mRNA Vaccine And Therapeutics 麻豆原创 Dynamics
2.3.1 mRNA Vaccine And Therapeutics Industry Trends
2.3.2 mRNA Vaccine And Therapeutics 麻豆原创 Drivers
2.3.3 mRNA Vaccine And Therapeutics 麻豆原创 Challenges
2.3.4 mRNA Vaccine And Therapeutics 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue mRNA Vaccine And Therapeutics by Players
3.1.1 Global mRNA Vaccine And Therapeutics Revenue by Players (2018-2023)
3.1.2 Global mRNA Vaccine And Therapeutics Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global mRNA Vaccine And Therapeutics 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of mRNA Vaccine And Therapeutics, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global mRNA Vaccine And Therapeutics 麻豆原创 Concentration Ratio
3.4.1 Global mRNA Vaccine And Therapeutics 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by mRNA Vaccine And Therapeutics Revenue in 2022
3.5 Global Key Players of mRNA Vaccine And Therapeutics Head office and Area Served
3.6 Global Key Players of mRNA Vaccine And Therapeutics, Product and Application
3.7 Global Key Players of mRNA Vaccine And Therapeutics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 mRNA Vaccine And Therapeutics Breakdown Data by Type
4.1 Global mRNA Vaccine And Therapeutics Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global mRNA Vaccine And Therapeutics Forecasted 麻豆原创 Size by Type (2024-2029)
5 mRNA Vaccine And Therapeutics Breakdown Data by Application
5.1 Global mRNA Vaccine And Therapeutics Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global mRNA Vaccine And Therapeutics Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America mRNA Vaccine And Therapeutics 麻豆原创 Size (2018-2029)
6.2 North America mRNA Vaccine And Therapeutics 麻豆原创 Size by Type
6.2.1 North America mRNA Vaccine And Therapeutics 麻豆原创 Size by Type (2018-2023)
6.2.2 North America mRNA Vaccine And Therapeutics 麻豆原创 Size by Type (2024-2029)
6.2.3 North America mRNA Vaccine And Therapeutics 麻豆原创 Share by Type (2018-2029)
6.3 North America mRNA Vaccine And Therapeutics 麻豆原创 Size by Application
6.3.1 North America mRNA Vaccine And Therapeutics 麻豆原创 Size by Application (2018-2023)
6.3.2 North America mRNA Vaccine And Therapeutics 麻豆原创 Size by Application (2024-2029)
6.3.3 North America mRNA Vaccine And Therapeutics 麻豆原创 Share by Application (2018-2029)
6.4 North America mRNA Vaccine And Therapeutics 麻豆原创 Size by Country
6.4.1 North America mRNA Vaccine And Therapeutics 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America mRNA Vaccine And Therapeutics 麻豆原创 Size by Country (2018-2023)
6.4.3 North America mRNA Vaccine And Therapeutics 麻豆原创 Size by Country (2024-2029)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe mRNA Vaccine And Therapeutics 麻豆原创 Size (2018-2029)
7.2 Europe mRNA Vaccine And Therapeutics 麻豆原创 Size by Type
7.2.1 Europe mRNA Vaccine And Therapeutics 麻豆原创 Size by Type (2018-2023)
7.2.2 Europe mRNA Vaccine And Therapeutics 麻豆原创 Size by Type (2024-2029)
7.2.3 Europe mRNA Vaccine And Therapeutics 麻豆原创 Share by Type (2018-2029)
7.3 Europe mRNA Vaccine And Therapeutics 麻豆原创 Size by Application
7.3.1 Europe mRNA Vaccine And Therapeutics 麻豆原创 Size by Application (2018-2023)
7.3.2 Europe mRNA Vaccine And Therapeutics 麻豆原创 Size by Application (2024-2029)
7.3.3 Europe mRNA Vaccine And Therapeutics 麻豆原创 Share by Application (2018-2029)
7.4 Europe mRNA Vaccine And Therapeutics 麻豆原创 Size by Country
7.4.1 Europe mRNA Vaccine And Therapeutics 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe mRNA Vaccine And Therapeutics 麻豆原创 Size by Country (2018-2023)
7.4.3 Europe mRNA Vaccine And Therapeutics 麻豆原创 Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China mRNA Vaccine And Therapeutics 麻豆原创 Size (2018-2029)
8.2 China mRNA Vaccine And Therapeutics 麻豆原创 Size by Type
8.2.1 China mRNA Vaccine And Therapeutics 麻豆原创 Size by Type (2018-2023)
8.2.2 China mRNA Vaccine And Therapeutics 麻豆原创 Size by Type (2024-2029)
8.2.3 China mRNA Vaccine And Therapeutics 麻豆原创 Share by Type (2018-2029)
8.3 China mRNA Vaccine And Therapeutics 麻豆原创 Size by Application
8.3.1 China mRNA Vaccine And Therapeutics 麻豆原创 Size by Application (2018-2023)
8.3.2 China mRNA Vaccine And Therapeutics 麻豆原创 Size by Application (2024-2029)
8.3.3 China mRNA Vaccine And Therapeutics 麻豆原创 Share by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia mRNA Vaccine And Therapeutics 麻豆原创 Size (2018-2029)
9.2 Asia mRNA Vaccine And Therapeutics 麻豆原创 Size by Type
9.2.1 Asia mRNA Vaccine And Therapeutics 麻豆原创 Size by Type (2018-2023)
9.2.2 Asia mRNA Vaccine And Therapeutics 麻豆原创 Size by Type (2024-2029)
9.2.3 Asia mRNA Vaccine And Therapeutics 麻豆原创 Share by Type (2018-2029)
9.3 Asia mRNA Vaccine And Therapeutics 麻豆原创 Size by Application
9.3.1 Asia mRNA Vaccine And Therapeutics 麻豆原创 Size by Application (2018-2023)
9.3.2 Asia mRNA Vaccine And Therapeutics 麻豆原创 Size by Application (2024-2029)
9.3.3 Asia mRNA Vaccine And Therapeutics 麻豆原创 Share by Application (2018-2029)
9.4 Asia mRNA Vaccine And Therapeutics 麻豆原创 Size by Region
9.4.1 Asia mRNA Vaccine And Therapeutics 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia mRNA Vaccine And Therapeutics 麻豆原创 Size by Region (2018-2023)
9.4.3 Asia mRNA Vaccine And Therapeutics 麻豆原创 Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America mRNA Vaccine And Therapeutics 麻豆原创 Size (2018-2029)
10.2 Middle East, Africa, and Latin America mRNA Vaccine And Therapeutics 麻豆原创 Size by Type
10.2.1 Middle East, Africa, and Latin America mRNA Vaccine And Therapeutics 麻豆原创 Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America mRNA Vaccine And Therapeutics 麻豆原创 Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America mRNA Vaccine And Therapeutics 麻豆原创 Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America mRNA Vaccine And Therapeutics 麻豆原创 Size by Application
10.3.1 Middle East, Africa, and Latin America mRNA Vaccine And Therapeutics 麻豆原创 Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America mRNA Vaccine And Therapeutics 麻豆原创 Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America mRNA Vaccine And Therapeutics 麻豆原创 Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America mRNA Vaccine And Therapeutics 麻豆原创 Size by Country
10.4.1 Middle East, Africa, and Latin America mRNA Vaccine And Therapeutics 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America mRNA Vaccine And Therapeutics 麻豆原创 Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America mRNA Vaccine And Therapeutics 麻豆原创 Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Argos Therapeutics
11.1.1 Argos Therapeutics Company Details
11.1.2 Argos Therapeutics Business Overview
11.1.3 Argos Therapeutics mRNA Vaccine And Therapeutics Introduction
11.1.4 Argos Therapeutics Revenue in mRNA Vaccine And Therapeutics Business (2018-2023)
11.1.5 Argos Therapeutics Recent Developments
11.2 BioNTech
11.2.1 BioNTech Company Details
11.2.2 BioNTech Business Overview
11.2.3 BioNTech mRNA Vaccine And Therapeutics Introduction
11.2.4 BioNTech Revenue in mRNA Vaccine And Therapeutics Business (2018-2023)
11.2.5 BioNTech Recent Developments
11.3 CureVac
11.3.1 CureVac Company Details
11.3.2 CureVac Business Overview
11.3.3 CureVac mRNA Vaccine And Therapeutics Introduction
11.3.4 CureVac Revenue in mRNA Vaccine And Therapeutics Business (2018-2023)
11.3.5 CureVac Recent Developments
11.4 eTheRNA
11.4.1 eTheRNA Company Details
11.4.2 eTheRNA Business Overview
11.4.3 eTheRNA mRNA Vaccine And Therapeutics Introduction
11.4.4 eTheRNA Revenue in mRNA Vaccine And Therapeutics Business (2018-2023)
11.4.5 eTheRNA Recent Developments
11.5 Ethris
11.5.1 Ethris Company Details
11.5.2 Ethris Business Overview
11.5.3 Ethris mRNA Vaccine And Therapeutics Introduction
11.5.4 Ethris Revenue in mRNA Vaccine And Therapeutics Business (2018-2023)
11.5.5 Ethris Recent Developments
11.6 In-Cell-Art
11.6.1 In-Cell-Art Company Details
11.6.2 In-Cell-Art Business Overview
11.6.3 In-Cell-Art mRNA Vaccine And Therapeutics Introduction
11.6.4 In-Cell-Art Revenue in mRNA Vaccine And Therapeutics Business (2018-2023)
11.6.5 In-Cell-Art Recent Developments
11.7 Moderna Therapeutics
11.7.1 Moderna Therapeutics Company Details
11.7.2 Moderna Therapeutics Business Overview
11.7.3 Moderna Therapeutics mRNA Vaccine And Therapeutics Introduction
11.7.4 Moderna Therapeutics Revenue in mRNA Vaccine And Therapeutics Business (2018-2023)
11.7.5 Moderna Therapeutics Recent Developments
11.8 Sangamo Therapeutics
11.8.1 Sangamo Therapeutics Company Details
11.8.2 Sangamo Therapeutics Business Overview
11.8.3 Sangamo Therapeutics mRNA Vaccine And Therapeutics Introduction
11.8.4 Sangamo Therapeutics Revenue in mRNA Vaccine And Therapeutics Business (2018-2023)
11.8.5 Sangamo Therapeutics Recent Developments
11.9 Tiba Biotechnology
11.9.1 Tiba Biotechnology Company Details
11.9.2 Tiba Biotechnology Business Overview
11.9.3 Tiba Biotechnology mRNA Vaccine And Therapeutics Introduction
11.9.4 Tiba Biotechnology Revenue in mRNA Vaccine And Therapeutics Business (2018-2023)
11.9.5 Tiba Biotechnology Recent Developments
11.10 Translate Bio
11.10.1 Translate Bio Company Details
11.10.2 Translate Bio Business Overview
11.10.3 Translate Bio mRNA Vaccine And Therapeutics Introduction
11.10.4 Translate Bio Revenue in mRNA Vaccine And Therapeutics Business (2018-2023)
11.10.5 Translate Bio Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Argos Therapeutics
BioNTech
CureVac
eTheRNA
Ethris
In-Cell-Art
Moderna Therapeutics
Sangamo Therapeutics
Tiba Biotechnology
Translate Bio
听
听
*If Applicable.
